This article has Open Peer Review reports available.
GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial
© The Author(s). 2017
Received: 19 January 2017
Accepted: 14 July 2017
Published: 26 July 2017
Open Peer Review reports
Pre-publication versions of this article and author comments to reviewers are available by contacting email@example.com.
|19 Jan 2017||Submitted||Original manuscript|
|14 Jun 2017||Reviewed||Reviewer Report - Joel Dubin|
|29 Jun 2017||Author responded||Author comments - Jamie Oughton|
|Resubmission - Version 2|
|29 Jun 2017||Submitted||Manuscript version 2|
|14 Jul 2017||Reviewed||Reviewer Report - Joel Dubin|
|Resubmission - Version 3|
|Submitted||Manuscript version 3|
|14 Jul 2017||Editorially accepted|
|26 Jul 2017||Article published||10.1186/s13063-017-2107-0|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting firstname.lastname@example.org. All previous versions of the manuscript and all author responses to the reviewers are also available.
You can find further information about the peer review system here.